CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy.


Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2022
Historique:
received: 13 04 2022
accepted: 14 06 2022
entrez: 22 7 2022
pubmed: 23 7 2022
medline: 26 7 2022
Statut: epublish

Résumé

Immunotherapy is a promising therapeutic area in cancer and chronic viral infections. An important component of immunotherapy in these contexts is the activation of innate immunity. Here we investigate the potential for CD169 (Siglec 1) expression on monocytes to serve as a robust biomarker for activation of innate immunity and, particular, as a proxy for IFN-α production. Specifically, we investigated the effects of

Identifiants

pubmed: 35865810
doi: 10.3389/fcimb.2022.919097
pmc: PMC9294151
doi:

Substances chimiques

Adjuvants, Immunologic 0
Biomarkers 0
Immunologic Factors 0
Sialic Acid Binding Ig-like Lectin 1 0
Toll-Like Receptor 9 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

919097

Informations de copyright

Copyright © 2022 Lende, Pahus, Monrad, Olesen, Mahr, Vibholm, Østergaard, Søgaard, Andersen, Denton and Tolstrup.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nucleic Acid Ther. 2015 Jun;25(3):130-40
pubmed: 25826686
Adv Drug Deliv Rev. 2008 Apr 29;60(7):786-94
pubmed: 18280610
Nat Immunol. 2015 Apr;16(4):343-53
pubmed: 25789684
Nat Immunol. 2010 May;11(5):373-84
pubmed: 20404851
PLoS Pathog. 2013;9(4):e1003291
pubmed: 23593001
Clin Infect Dis. 2010 Jul 1;51(1):42-50
pubmed: 20504165
J Virol. 2017 Oct 13;91(21):
pubmed: 28794041
Arthritis Rheum. 2007 Mar;56(3):1010-20
pubmed: 17328080
Sci Transl Med. 2021 Jun 23;13(599):
pubmed: 34162752
J Infect Dis. 2021 Feb 24;223(4):562-567
pubmed: 33206973
Clin Infect Dis. 2021 Jun 1;72(11):e815-e824
pubmed: 33043969
AIDS Rev. 2011 Jul-Sep;13(3):135-48
pubmed: 21799532
Nat Biotechnol. 2014 Apr;32(4):364-72
pubmed: 24633240
Am J Cancer Res. 2020 Dec 01;10(12):4568-4584
pubmed: 33415020
PLoS One. 2020 Oct 29;15(10):e0241375
pubmed: 33119684
Adv Exp Med Biol. 2020;1204:197-214
pubmed: 32152948
Glycobiology. 2014 Sep;24(9):818-25
pubmed: 24996821
Clin Microbiol Rev. 2009 Apr;22(2):240-73, Table of Contents
pubmed: 19366914
J Virol. 2019 Apr 3;93(8):
pubmed: 30700598
J Cancer Res Clin Oncol. 2014 Sep;140(9):1615-24
pubmed: 24816725
Blood Adv. 2018 Nov 13;2(21):2862-2878
pubmed: 30381402
Front Immunol. 2020 Jun 11;11:1112
pubmed: 32595636
Cancer Immunol Res. 2015 Dec;3(12):1356-63
pubmed: 26297710
Immunology. 2019 Jun;157(2):163-172
pubmed: 30919991
EBioMedicine. 2019 Jan;39:173-181
pubmed: 30579863
Nat Rev Drug Discov. 2006 Jun;5(6):471-84
pubmed: 16763660
Clin Infect Dis. 2017 Jun 15;64(12):1686-1695
pubmed: 28329286
Vaccine. 2016 May 27;34(25):2847-54
pubmed: 27102821
Eur J Cancer. 2015 Jan;51(2):146-56
pubmed: 25480557
J Immunol. 2002 May 1;168(9):4531-7
pubmed: 11970999
Crit Rev Oncol Hematol. 2015 Apr;94(1):31-44
pubmed: 25577571
J Virol. 2016 Apr 14;90(9):4441-4453
pubmed: 26889036
PLoS Biol. 2012;10(12):e1001448
pubmed: 23271952
EBioMedicine. 2019 Jul;45:328-340
pubmed: 31300344
J Transl Med. 2016 Feb 09;14:44
pubmed: 26861779
Viruses. 2019 Dec 19;12(1):
pubmed: 31861617
Retrovirology. 2015 May 07;12:37
pubmed: 25947229
Glycoconj J. 1997 Aug;14(5):601-9
pubmed: 9298693
Cancer Discov. 2021 Dec 1;11(12):2998-3007
pubmed: 34326162
J Vis Exp. 2020 Jan 31;(155):
pubmed: 32065160
Nat Commun. 2016 Aug 11;7:12412
pubmed: 27510803
AIDS Res Hum Retroviruses. 2015 Jul;31(7):696-706
pubmed: 25891017
Mucosal Immunol. 2018 Mar;11(2):449-461
pubmed: 28766555
AIDS. 2019 Jul 1;33(8):1315-1325
pubmed: 30932955
J Exp Med. 2002 Aug 19;196(4):517-27
pubmed: 12186843
Infect Immun. 2012 May;80(5):1744-52
pubmed: 22371375

Auteurs

Stine Sofie Frank Lende (SSF)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Marie Høst Pahus (MH)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Ida Monrad (I)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Rikke Olesen (R)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Anna R Mahr (AR)

Department of Biology, University of Nebraska at Omaha, Omaha, NE, United States.

Line K Vibholm (LK)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Lars Østergaard (L)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Ole Schmeltz Søgaard (OS)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Anna Halling Folkmar Andersen (AHF)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Paul W Denton (PW)

Department of Biology, University of Nebraska at Omaha, Omaha, NE, United States.

Martin Tolstrup (M)

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH